Plus   Neg

Medtronic Raises FY19 Organic Revenue Outlook - Quick Facts

Medtronic plc (MDT) on Tuesday reported second-quarter net income of $1.12 billion or $0.82 per share.

Adjusted earnings per share for the quarter increased 14 percent from the year-ago period to $1.22. Adjusting for a positive $0.01 impact from foreign currency, adjusted earnings per share increased 13 percent.

Worldwide revenue for the quarter rose 6.1 percent to $7.48 billion. On an organic basis, which adjusts for a $95 million negative impact from foreign currency, revenue increased 7.5 percent.

On average, analyst polled by Thomson Reuters expected the company to report earnings of $1.15 per share for the quarter on revenues of $7.35 billion. Analysts' estimates typically exclude special items.

Looking ahead to fiscal year 2019, Medtronic maintained its outlook for adjusted earnings in a range of $5.10 to $5.15 per share. The company noted that if recent exchange rates hold for the remainder of the fiscal year, foreign exchange would have a neutral impact on the company's fiscal year 2019 earnings per share, implying a constant currency earnings per share growth forecast of 9 to 10 percent

The company raised its forecast for full-year organic revenue growth from a range of 4.5 to 5.0 percent to a range of 5.0 to 5.5 percent. If recent exchange rates hold for the remainder of the fiscal year, the company's fiscal year 2019 revenue would be negatively affected by approximately $420 million to $520 million.

The Street expects earnings of $5.12 per share for the year on revenues of $30.46 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT